MedTrace Logo

Curative D2 vs D1 Lymphadenectomy in Operable Gastric Carcinoma

NCT04340440 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-04-10

No results posted yet for this study

Summary

Gastric carcinoma is the second most common cause of cancer-related deaths and its main treatment modality if potentially curable is surgery but the optimal surgical resection is controversial. The aim of the current study was to assess the outcomes of curative D2 compared to D1 gastrectomy of operable gastric carcinoma regarding postoperative morbidity and mortality, disease recurrence and survival rates.

Conditions

Interventions

PROCEDURE

D1 lymphadenectomy

Radical gastrectomy with D1 lymphadenectomy

PROCEDURE

D2 lymphadenectomy

Radical gastrectomy with D2 lymphadenectomy

Sponsors & Collaborators

  • University of Alexandria

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-09-30
Completion
2020-02-29

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04340440 on ClinicalTrials.gov